Medical oncologist Alexander Lesokhin discusses a phase I dose escalation of an anti-PD-1 immunotherapy in patients with hematologic cancers.
Medical oncologist Steven M. Horwitz discusses the development and impact of three new, widely used therapies for T cell lymphoma: pralatrexate, romidepsin, and brentuximab vedotin.
Chief of the Lymphoma Service Andrew Zelenetz discusses a retrospective review examining the frequency of FDG avidity across a range of lymphoma histologies.
Medical oncologist David Straus discusses how sequential bexarotene does not increase response rate in patients with Kaposi's sarcoma.
Medical oncologist Matthew Matasar discusses the inclusion of OFA in second-line therapy for aggressive or relapsing B-cell non-Hodgkin’s lymphoma.
Clinical Director of the Lymphoma Outpatient Unit Paul Hamlin discusses relationship between DLT and SAE with increasing age and comorbidities in lymphoma trials.
Our specialists care for more than 1,200 individuals newly diagnosed with lymphoma each year, as well as many others receiving ongoing and follow-up care. A multidisciplinary team of physicians that includes medical and radiation oncologists and surgeons focuses its expertise on each case, personalizing care.
Most patients with Hodgkin lymphoma have very good outcomes at our institution, and recent second-line treatment strategies have improved prospects for positive tumor response, reduced toxicity, and increased stem cell harvest for transplantation in patients with relapse. Recent data (2010) indicate a five-year cure rate of nearly 70 percent for patients following autologous transplant for relapsed Hodgkin lymphoma, compared to national averages of 45 to 50 percent as reported by the Bone Marrow Transplant Registry.
Our expertise in common as well as rare forms of non-Hodgkin lymphoma is similarly comprehensive, and we are pioneering advances in novel treatment approaches. A recent example is the introduction of a chemotherapy regimen that adds three new agents (ICE) to the standard R-CHOP formula to improve outcomes for high-risk patients with advanced and aggressive disease.